News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Apex and Polygon launch compliance chain for tokenized RWAs
Cointelegraph·2026/03/19 13:03
Crypto hacks average $25 million as largest exploits skew industry losses: Immunefi
The Block·2026/03/19 13:01
Best Crypto Presale ROI in 2026? IPO Genie ($IPO) Targets 20x Return Before Exchange Listings
BlockchainReporter·2026/03/19 13:01
Russia’s push for AI expansion threatens to undermine crypto mining
Cryptopolitan·2026/03/19 12:46
U Power Limited Announces Pricing of $6.0 Million Public Offering
Finviz·2026/03/19 12:46
Evolent announces appointment of Archie Mayani as chief product officer
Finviz·2026/03/19 12:46
Ramadan: How to Pay Zakat on Your Crypto Wealth
DeFi Planet·2026/03/19 12:46
Momentum Shift for FARTCOIN: Will It Stay Range-Bound?
post-159760
post-159760
post-159760
Newscrypto·2026/03/19 12:43
Crypto Market Cap Drops as Bitcoin Tests $70K
Coinomedia·2026/03/19 12:42
Crypto Market Cap Drops as Bitcoin Tests $70K
Coinomedia·2026/03/19 12:42
Flash
20:09
Five Below shares dropped 8% in after-hours US tradingThe company's net sales in the first quarter were $1.29 billion.
20:06
U.S. stocks close lower: the three major indexes ended in the red, NVIDIA fell more than 3%According to Golden Ten Data on June 4, U.S. stocks closed lower on Wednesday, with the Dow Jones initially down 1.2%, the S&P 500 down 0.7%, and the Nasdaq down 0.89%. Microsoft (MSFT.O) and NVIDIA (NVDA.O) both fell more than 3%, Oracle (ORCL.N) dropped over 5%, while Intel (INTC.O) rose 4%. The Nasdaq Golden Dragon China Index closed down 2.46%, with Alibaba (BABA.N) slipping more than 2%.
20:06
Verastem Oncology announced that its oral, potential best-in-class investigational KRAS G12D (on/off) inhibitor VS-7375 has received Fast Track designation from the U.S. Food and Drug Administration (FDA).This medication is intended for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying the KRAS G12D mutation. Fast Track designation is designed to accelerate the development and review process for drugs aimed at serious conditions that address unmet medical needs. This designation means that VS-7375 has the potential to address the critical clinical need in KRAS G12D-mutant NSCLC. For Verastem, this represents an important regulatory milestone in advancing its product pipeline.